Podium to Practice: Chicago 2026 – MELANOMA: ADAM & STAMP

Podium to Practice: Chicago 2026 – MELANOMA: ADAM & STAMP

Podium to Practice: Chicago 2026

Studies / Trials Discussed

9504 – ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.

9505 -Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174.

Icon Chair Speaker

Chair

Dr. Vanessa Bernstein

Icon Chair Speaker

Speakers

Dr. Marcus Butler

Prof. Caroline Robert

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

9504 – ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases. 9505 -Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174.
Tagged